French pharma Sanofi is set to buy Kiadis for a total of €308 ($358m) for access to the biotech’s NK-cell technology platform and pipeline.
Following the acquisition, Sanofi will be able to fully access Kiaidis’ off-the-shelf natural killer (NK) cell platform.
This platform is based on NK-cells from a ‘unique universal donor’, which Kiadis says has the potential to make NK-cell therapy products available quickly and economically for a potentially wider range of indications.
Part of Sanofi’s rationale for acquiring Kiaidis is to take control of this proprietary platform, while another focus will be on the NK-cell specialist’s pipeline products, which Sanofi hopes will complement its push into immuno-oncology.
Sanofi licensed Kiadis’ pre-clinical K-NK004 programme for multiple myeloma in July, to use in combination with its CD38 inhibitor, Sarclisa.
Other pipeline products include K-NK002, currently in phase 2 development for the prevention of post-transplant relapse in patients with acute myeloid leukaemia AML and myelodysplastic syndromes.
Read more: http://www.pmlive.com/pharma_news/sanofi_set_to_acquire_kiadis_for_308m_1355944